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ABSTRACT 
 
Metabolic syndrome is a group of risk factors including an increased level of triglycerides, fasting blood 
glucose, blood pressure or waist circumference, and or a decreased level of HDL cholesterol. The level of uric 
acid in the blood has been associated with the presence of metabolic syndrome, which can aggravate the 
prognosis of cardiovascular diseases, type 2 diabetes mellitus and stroke. On the interest to identify the early 
biomarkers of metabolic syndrome, Popovic et al involved 1333 patients and showed using logistic regression 
that a significant association between the blood levels of uric acid in the subjects diagnosed with metabolic 
syndrome and in the group of obese patients, who had the body mass index of more than 30 kg/m2. This 
study shed some light in identifying a metabolically unhealthy phenotype.    . 
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Uric acid and metabolic syndrome 
Metabolic syndrome (MS) is identified in an 
individual, who is having three or more of the 
following five risk factors such as (i) large waist 
circumference or central adiposity, (ii) higher level of 
triglycerides, (iii) lower level of HDL cholesterol, (iv) 
higher level of fasting blood glucose (v) and increased 
blood pressure.1 Ultimately, carrying these risk factors 
can worsen the prognosis of cardiovascular diseases, 
type-2 diabetes mellitus and stroke. Thus, in order to 
prevent the development of MS, it is important to 
identify the early biomarkers, which can increase the 
incidence of MS. Recently, uric acid has gained some 
clinical interest as hyperuricemia is comorbid with MS 
and type-2 diabetes.2  
The cross sectional study of Popovic DS et al3 
involving 1333 patients from Vojvodina region of 
Serbia tested the serum uric acid level in separate 
groups of normal weight (body mass index (BMI) of 
18.5 - 25 kg/m2), overweight (BMI of 25-30 kg/m2), 
and obese (BMI of greater than 30 kg/m2) persons, 
and further characterized them for the presence or 
absence of MS.   The results show that the serum uric 
acid level was significantly higher in subjects diagnosed 
with MS in both overall study group and in the group 
of obese subjects.   
 
Uric acid: a pro-oxidant or an anti-oxidant? 
In humans, uric acid is generated at the end of 
purine metabolism via the activity of xanthine oxidase 
(XO) primarily in the liver. About two thirds of total 
body urate is produced endogenously (recycling of 
cellular materials), and the remaining one third is 
originated from dietary purines (purine rich food 
include organ meat like kidney, and seafood).  
In accordance with the results shown by the 
Popovic et al3, there has been an association between 
the level of uric acid and MS risk; and hyperuricaemia 
alone disturbs the normal metabolism, causing insulin 
resistance and could lead to MS.4 A recent meta-
analysis study identified that an elevated serum uric 
acid level was a causal factor contributed to an 
increased risk of MS, showing that each 1 mg/dl 
increase in the serum uric acid level was associated 
with a 30% increase in the MS risk.5 Several in-vitro 
studies show that oxidative stress is the primary 
mechanism in causing damage to the vascular, renal, 
liver cells and adipocytes exposed to uric acid.6 The 
role of reactive oxygen species in causing local 
inflammation, impaired nitric oxide generation, leading 
to insulin resistance and fat accumulation is well 
known. Nevertheless, it is paradoxical that uric acid 
acts as an important antioxidant in the body, by 
scavenging oxygen radicals such as single oxygen 
peroxyl and hydroxyl radicals (but not superoxide 
radicals), and can also react with peroxynitrite to 
stabilize endothelial nitric oxide synthase (eNOS) 
activity and prevents peroxynitrite- induced protein 
nitrosylation.6  
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Several mechanisms have been suggested for 
the various physiological and pathological roles of uric 
acid. Uric acid might function as a pro-oxidant inside 
the cells (mediated through NADPH oxidase-
dependent pathway), whereas it act as an antioxidant 
in soluble form in the extracellular milieu.6 The 
following three mechanisms have been proposed for 
the association between serum uric acid and 
development of MS, such as (i) a decreased renal uric 
acid excretion, (ii) an impaired endothelial function 
leading to insulin resistance, and (iii) the inflammation 
and the changes in the oxidative status of adipocytes 
induced by uric acid. 
 
Future Directions 
Uric acid appears to be a significant 
independent predictor of vascular and renal disease in 
hypertensive patients and in subjects with high risk 
factors, such as diabetes, patients with chronic kidney 
disease or congestive heart failure.7, 8 Although a few 
studies have mentioned as serum uric acid is a very 
weak predictor of cardiovascular disease,9 the level of 
uric acid could be used as a marker to identify the 
“metabolically unhealthy” phenotype, as mentioned by 
Popovic et al.3 Yet, the exact role of the higher level of 
uric acid in inducing the metabolic syndrome is 
unknown, and whether uric acid independently 
contributes to the development of MS or it is merely a 
by-product of other processes, and whether uric acid 
can act as a biomarker to predict the future 
development of MS is remain to be debated. This is 
because, currently there is no published results 
available using uric acid-lowering therapy in a large 
population, although some randomized controlled 
studies are ongoing now to examine the etiologic role 
of hyperuricemia on the progression of cardiovascular, 
renal and metabolic diseases. Moreover, it would be 
interesting to study the molecular mechanism that 
converts uric acid from anti-oxidant to pro-oxidant in 
hypertensive and/or diabetic subjects with high 
cardiovascular risk factors 
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